MA33467B1 - Promédicaments comprenant un conjugué insuline-lieur - Google Patents
Promédicaments comprenant un conjugué insuline-lieurInfo
- Publication number
- MA33467B1 MA33467B1 MA34582A MA34582A MA33467B1 MA 33467 B1 MA33467 B1 MA 33467B1 MA 34582 A MA34582 A MA 34582A MA 34582 A MA34582 A MA 34582A MA 33467 B1 MA33467 B1 MA 33467B1
- Authority
- MA
- Morocco
- Prior art keywords
- insulin
- binding
- drugs include
- include insulin
- primary drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN PROMÉDICAMENT OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, CONTENANT UN CONJUGUÉ D-L ASSOCIANT UNE SÉQUENCE DE LIAISON ET DE L'INSULINE, D REPRÉSENTANT LA FRACTION INSULINE ET -L LA FRACTION SÉQUENCE DE LIAISON NON BIOLOGIQUEMENT ACTIVE -L1 DE FORMULE (I), LE POINTILLÉ INDIQUANT LA LIAISON À L'UN DES GROUPES AMINÉS DE L'INSULINE PAR FORMATION D'UNE LIAISON AMIDE. L'INVENTION CONCERNE, EN OUTRE, DES COMPOSITIONS PHARMACEUTIQUES CONTENANT LESDITS PROMÉDICAMENTS, AINSI QUE LEUR UTILISATION EN TANT QUE MÉDICAMENTS À DES FINS DE TRAITEMENT OU DE PRÉVENTION DE MALADIES OU D'AFFECTIONS POUVANT ÊTRE TRAITÉES PAR L'INSULINE.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09167027 | 2009-07-31 | ||
EP09174525 | 2009-10-29 | ||
EP09179336 | 2009-12-15 | ||
EP09179818 | 2009-12-18 | ||
PCT/EP2010/061159 WO2011012718A1 (fr) | 2009-07-31 | 2010-07-30 | Promédicaments contenant un conjugué associant une séquence de liaison et de l'insuline |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33467B1 true MA33467B1 (fr) | 2012-07-03 |
Family
ID=42670465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34582A MA33467B1 (fr) | 2009-07-31 | 2010-07-30 | Promédicaments comprenant un conjugué insuline-lieur |
Country Status (21)
Country | Link |
---|---|
US (2) | US9138462B2 (fr) |
EP (1) | EP2459228B1 (fr) |
JP (1) | JP5738291B2 (fr) |
KR (1) | KR20120089843A (fr) |
CN (1) | CN102548583B (fr) |
AU (1) | AU2010277559B2 (fr) |
BR (1) | BR112012002168A2 (fr) |
CA (1) | CA2769340C (fr) |
CL (1) | CL2012000248A1 (fr) |
CO (1) | CO6491083A2 (fr) |
CR (1) | CR20120018A (fr) |
IL (1) | IL217778A (fr) |
MA (1) | MA33467B1 (fr) |
MX (1) | MX2012001399A (fr) |
NI (1) | NI201200012A (fr) |
NZ (1) | NZ598021A (fr) |
PE (1) | PE20120918A1 (fr) |
SG (1) | SG178193A1 (fr) |
TN (1) | TN2012000011A1 (fr) |
WO (1) | WO2011012718A1 (fr) |
ZA (1) | ZA201200223B (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8377917B2 (en) * | 2004-03-23 | 2013-02-19 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
EP2459228B1 (fr) | 2009-07-31 | 2020-03-04 | Sanofi-Aventis Deutschland GmbH | Promédicament comprenant un conjugué insuline-lieur |
DK2459171T3 (en) | 2009-07-31 | 2017-09-25 | Sanofi Aventis Deutschland | Long-acting insulin composition |
JP5912112B2 (ja) | 2010-06-24 | 2016-04-27 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | アミド系インスリンプロドラッグ |
EP2438930A1 (fr) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Promédicaments comprenant un conjugué de liaison d'exendine |
JP6392123B2 (ja) | 2011-12-20 | 2018-09-19 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation | 糖尿病治療のためのctp系インスリンアナローグ |
CN104981251B (zh) | 2012-09-26 | 2018-03-20 | 印第安纳大学研究及科技有限公司 | 胰岛素类似物二聚体 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
JP6271566B2 (ja) * | 2012-10-11 | 2018-01-31 | アセンディス ファーマ エー/エス | ヒドロゲルプロドラッグ |
EP2934569A1 (fr) | 2012-12-21 | 2015-10-28 | Sanofi | Dérivés de l'exendine 4 |
CA2904332A1 (fr) * | 2013-03-14 | 2014-10-02 | Indiana University Research And Technology Corporation | Conjugues d'insuline-incretine |
EP3054982B1 (fr) * | 2013-10-08 | 2019-05-01 | Ascendis Pharma A/S | Promédicament de il-1ra lié à un hydrogel |
TW201605489A (zh) * | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素(insulin glulisine)的穩定調配物 |
WO2015086733A1 (fr) | 2013-12-13 | 2015-06-18 | Sanofi | Agonistes mixtes des récepteurs du glp-1/glucagon |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080152A1 (fr) | 2013-12-13 | 2016-10-19 | Sanofi | Analogues peptidiques de l'exendine 4 non acylés |
TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重glp-1/gip受體促效劑 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
WO2016049190A1 (fr) | 2014-09-24 | 2016-03-31 | Indiana University Research And Technology Corporation | Conjugués d'insuline-incrétines |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
US20200276276A1 (en) | 2016-03-01 | 2020-09-03 | Ascendis Pharma Bone Diseases A/S | PTH Prodrugs |
CA3030422C (fr) | 2016-07-13 | 2021-10-26 | Reform Biologics, Llc | Excipients stabilisants pour formulations de proteines therapeutiques |
EP4275677A3 (fr) | 2016-09-29 | 2024-01-10 | Ascendis Pharma Bone Diseases A/S | Schéma posologique pour composé pth à libération controlée |
WO2018060312A1 (fr) | 2016-09-29 | 2018-04-05 | Ascendis Pharma Bone Diseases A/S | Composés de pth ayant un faible rapport entre le pic et le niveau minimum |
TW201832783A (zh) * | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
EP3624828A4 (fr) | 2017-05-18 | 2021-03-03 | Merck Sharp & Dohme Corp. | Formulation pharmaceutique comprenant des conjugués d'incrétine-insuline |
AR112480A1 (es) | 2017-08-24 | 2019-10-30 | Novo Nordisk As | Composiciones de glp-1 y sus usos |
UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
US20230082544A1 (en) | 2020-02-18 | 2023-03-16 | Novo Nordisk A/S | Pharmaceutical formulations |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
DK257988D0 (da) | 1988-05-11 | 1988-05-11 | Novo Industri As | Nye peptider |
DE3837825A1 (de) | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
AU641631B2 (en) | 1988-12-23 | 1993-09-30 | Novo Nordisk A/S | Human insulin analogues |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
DK155690D0 (da) | 1990-06-28 | 1990-06-28 | Novo Nordisk As | Nye peptider |
US5634943A (en) | 1990-07-12 | 1997-06-03 | University Of Miami | Injectable polyethylene oxide gel implant and method for production |
AU673160B2 (en) | 1992-02-28 | 1996-10-31 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
US5514379A (en) | 1992-08-07 | 1996-05-07 | The General Hospital Corporation | Hydrogel compositions and methods of use |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
DE19626762A1 (de) | 1996-07-03 | 1998-01-08 | Basf Ag | Enzymatisch spaltbare Linker für Festphasensynthesen |
US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
US7157555B1 (en) | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
AU756836B2 (en) | 1997-11-14 | 2003-01-23 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
NZ504258A (en) | 1997-11-14 | 2002-12-20 | Amylin Pharmaceuticals Inc | Exendin 3 and 4 agonist compounds for the treatment of diabetes |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
AU1825299A (en) | 1997-12-17 | 1999-07-05 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
JP3786832B2 (ja) | 1998-01-07 | 2006-06-14 | デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム | 分解性のヘテロ二官能性ポリ(エチレングリコール)アクリレート及びそれから誘導されるゲル及び複合体 |
AU759058C (en) | 1998-02-13 | 2005-09-15 | Amylin Pharmaceuticals, Inc. | Inotropic and diuretic effects of exendin and GLP-1 |
CA2346329A1 (fr) | 1998-10-09 | 2000-04-20 | Kamal H. Bouhadir | Hydrogels et supports polymeres solubles dans l'eau pour administration de medicaments |
AU2707500A (en) | 1998-12-04 | 2000-06-26 | Incept Llc | Biocompatible crosslinked polymers |
MXPA01007777A (es) | 1999-02-01 | 2003-10-06 | Eidgenoess Tech Hochschule | Bio-materiales formadas por reaccion de adicion nucleofila a grupos insaturados conjugados. |
CA2499211A1 (fr) | 1999-05-17 | 2000-11-23 | Conjuchem Inc. | Peptides yy modifies et conjugues de ceux-ci |
US6506724B1 (en) | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
JP2003503367A (ja) | 1999-06-11 | 2003-01-28 | シアウォーター・コーポレイション | キトサンとポリ(エチレングリコール)または関連ポリマーから得られるヒドロゲル |
US6372813B1 (en) | 1999-06-25 | 2002-04-16 | Motorola | Methods and compositions for attachment of biomolecules to solid supports, hydrogels, and hydrogel arrays |
US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
CA2398788A1 (fr) | 2000-01-28 | 2001-08-02 | Infimed Therapeutics, Inc. | Polymeres contenant des proteines a liberation lente |
US6884778B2 (en) | 2000-04-14 | 2005-04-26 | William Marsh Rice University | Biocompatible macromers |
US7291673B2 (en) | 2000-06-02 | 2007-11-06 | Eidgenossiche Technische Hochschule Zurich | Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds |
JP4841066B2 (ja) | 2000-09-01 | 2011-12-21 | ライスユニバーシティ | 酸化窒素生成ヒドロゲル物質 |
US6537569B2 (en) | 2001-02-14 | 2003-03-25 | Microvention, Inc. | Radiation cross-linked hydrogels |
EP1243276A1 (fr) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Prodrogues activables à séparateurs allongés et multiples |
JP4340067B2 (ja) | 2001-04-23 | 2009-10-07 | ウィスコンシン アルムニ リサーチ ファウンデイション | 二機能性改変ハイドロゲル |
AP1763A (en) | 2001-05-21 | 2007-08-02 | Nektar Therapeutics | Pulmonary administration of chemically modified insulin |
ATE381963T1 (de) | 2001-10-26 | 2008-01-15 | Octoplus Technologies B V | Verfahren zur herstellung von gereinigten partikeln |
US6960298B2 (en) | 2001-12-10 | 2005-11-01 | Nanogen, Inc. | Mesoporous permeation layers for use on active electronic matrix devices |
US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
CA2479810A1 (fr) | 2002-04-04 | 2003-10-16 | Enzon, Inc. | Derives acyles polymeriques d'indoles |
DE10221457A1 (de) | 2002-05-15 | 2003-11-27 | Behr Gmbh & Co | Wärmeübertrager und Verfahren zu seiner Herstellung |
EP1531868A2 (fr) | 2002-06-03 | 2005-05-25 | Alnis Biosciences, Inc. | Agents therapeutiques contenant des nano-polymeres |
CA2487077A1 (fr) | 2002-06-10 | 2003-12-18 | Merck & Co., Inc. | Molecule d'acide nucleique isolee codant une proteine de type moteur associee a un centromere, et ses utilisations |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2004043493A1 (fr) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Promedicaments conçus en tant qu'espaceurs de liberation multiple a elimination automatique |
EP1620118B1 (fr) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Medicaments pegyles reversibles |
EP1525890A1 (fr) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Complexes protéine-protéophore |
US8377917B2 (en) * | 2004-03-23 | 2013-02-19 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
EP1586334A1 (fr) | 2004-04-15 | 2005-10-19 | TRASTEC scpa | G-CSF conjugés avec PEG |
US8728525B2 (en) | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
EP1625856A1 (fr) * | 2004-08-13 | 2006-02-15 | Complex Biosystems GmbH | Hydrogel conjugé polymèrique d'une prodrogue |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
JPWO2006038462A1 (ja) | 2004-10-01 | 2008-05-15 | 国立大学法人九州大学 | 新規ステロイド産生細胞 |
DE102004051715A1 (de) | 2004-10-23 | 2005-06-30 | Clariant Gmbh | Flüssigwaschmittel enthaltend Farbfixiermittel |
US7678551B2 (en) | 2004-10-25 | 2010-03-16 | Seradyn, Inc. | Immunoassays for lamotrigine |
US20060115865A1 (en) | 2004-10-25 | 2006-06-01 | Anlong Ouyang | Lamotrigine analogs |
US7407117B2 (en) | 2004-10-28 | 2008-08-05 | Meadwestvaco Calmar, Inc. | Liquid sprayer assembly |
JP2006163996A (ja) | 2004-12-09 | 2006-06-22 | Evolium Sas | 行動履歴に基づくプッシュ型の情報提供システム |
JP2008526846A (ja) | 2005-01-05 | 2008-07-24 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 鎮痛性結合体 |
KR100665672B1 (ko) | 2005-04-13 | 2007-01-09 | 성균관대학교산학협력단 | 새로운 온도 및 pH 민감성 블록 공중합체 및 이를 이용한고분자 하이드로겔 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US8039432B2 (en) | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
WO2007082088A2 (fr) | 2006-01-12 | 2007-07-19 | Histogenics Corporation | Procede de reparation et de reconstruction de ligaments ou de tendons rompus ou de traitement de lesions ligamentaires et tendineuses |
DE602006007679D1 (de) | 2006-03-31 | 2009-08-20 | Sony Deutschland Gmbh | Verfahren zur Herstellung eines vernetzten Polymer-Gels |
EP2021094A4 (fr) | 2006-05-25 | 2010-02-10 | Gen Hospital Corp | Agents anti-réticulation et procédés permettant de bloquer la réticulation de préparations d'hydrogel injectables |
CN101573133B (zh) * | 2006-07-31 | 2014-08-27 | 诺沃-诺迪斯克有限公司 | Peg化延长的胰岛素 |
CA2662978A1 (fr) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Segments de liaison biodegradables a base d'ester encombre pour distribution d'oligonuclotides |
US20080187568A1 (en) | 2007-02-06 | 2008-08-07 | Sawhney Amarpreet S | Polymerization with precipitation of proteins for elution in physiological solution |
US20080220047A1 (en) | 2007-03-05 | 2008-09-11 | Sawhney Amarpreet S | Low-swelling biocompatible hydrogels |
WO2008116913A2 (fr) | 2007-03-28 | 2008-10-02 | Novo Nordisk A/S | Composés peptidiques à pégylation biodégradable transitoire |
EP2136850B1 (fr) | 2007-04-13 | 2012-02-01 | Kuros Biosurgery AG | Agent de scellement tissulaire polymère |
US9353170B2 (en) | 2007-06-08 | 2016-05-31 | Sanofi-Aventis Deutschland Gmbh | Long-acting transient polymer conjugates of exendin |
EP2017288A1 (fr) * | 2007-07-16 | 2009-01-21 | Novo Nordisk A/S | Analogues de l'insuline pégylés, stabilisés à la protéase |
EP2170945A1 (fr) * | 2007-07-16 | 2010-04-07 | Novo Nordisk A/S | Analogues pegylés de l'insuline, stabilisés vis-à-vis des protéases |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
JP5588354B2 (ja) * | 2008-02-01 | 2014-09-10 | アセンディス ファーマ エー/エス | 自己切断可能なリンカーを含むプロドラッグ |
EP2247645B1 (fr) | 2008-02-13 | 2017-12-06 | Hyperbranch Medical Technology, Inc. | Hydrogels à base de polyalkylèneimines réticulées à taux de dégradation ajustable |
EP3000462A1 (fr) | 2008-04-28 | 2016-03-30 | Zogenix, Inc. | Compositions inédites destinées au traitement de la migraine |
SI3050576T1 (sl) | 2008-04-29 | 2021-08-31 | Ascendis Pharma Endocrinology Division A/S | Spojine pegiliranega rekombinantnega humanega rastnega hormona |
RU2011140219A (ru) | 2009-03-05 | 2013-04-10 | Асцендис Фарма Ас | Пролекарства интерферона альфа на носителе |
EP2459228B1 (fr) | 2009-07-31 | 2020-03-04 | Sanofi-Aventis Deutschland GmbH | Promédicament comprenant un conjugué insuline-lieur |
RU2554854C9 (ru) * | 2009-07-31 | 2017-02-03 | Асцендис Фарма Ас | Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля |
DK2459171T3 (en) | 2009-07-31 | 2017-09-25 | Sanofi Aventis Deutschland | Long-acting insulin composition |
KR101756493B1 (ko) | 2009-10-29 | 2017-07-10 | 아센디스 파마 에이에스 | 생분해성 하이드로겔의 살균 |
EP2438930A1 (fr) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Promédicaments comprenant un conjugué de liaison d'exendine |
-
2010
- 2010-07-30 EP EP10743076.1A patent/EP2459228B1/fr active Active
- 2010-07-30 AU AU2010277559A patent/AU2010277559B2/en not_active Ceased
- 2010-07-30 US US13/387,940 patent/US9138462B2/en not_active Expired - Fee Related
- 2010-07-30 BR BR112012002168A patent/BR112012002168A2/pt not_active Application Discontinuation
- 2010-07-30 KR KR1020127005591A patent/KR20120089843A/ko not_active Application Discontinuation
- 2010-07-30 MA MA34582A patent/MA33467B1/fr unknown
- 2010-07-30 WO PCT/EP2010/061159 patent/WO2011012718A1/fr active Application Filing
- 2010-07-30 CA CA2769340A patent/CA2769340C/fr not_active Expired - Fee Related
- 2010-07-30 PE PE2012000136A patent/PE20120918A1/es not_active Application Discontinuation
- 2010-07-30 MX MX2012001399A patent/MX2012001399A/es active IP Right Grant
- 2010-07-30 JP JP2012522188A patent/JP5738291B2/ja not_active Expired - Fee Related
- 2010-07-30 SG SG2012006821A patent/SG178193A1/en unknown
- 2010-07-30 CN CN201080043925.4A patent/CN102548583B/zh not_active Expired - Fee Related
- 2010-07-30 NZ NZ598021A patent/NZ598021A/en not_active IP Right Cessation
-
2012
- 2012-01-05 TN TNP2012000011A patent/TN2012000011A1/en unknown
- 2012-01-11 ZA ZA2012/00223A patent/ZA201200223B/en unknown
- 2012-01-12 CR CR20120018A patent/CR20120018A/es unknown
- 2012-01-25 NI NI201200012A patent/NI201200012A/es unknown
- 2012-01-26 CO CO12011783A patent/CO6491083A2/es active IP Right Grant
- 2012-01-26 IL IL217778A patent/IL217778A/en not_active IP Right Cessation
- 2012-01-30 CL CL2012000248A patent/CL2012000248A1/es unknown
-
2015
- 2015-05-14 US US14/712,369 patent/US9457066B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20150258207A1 (en) | 2015-09-17 |
EP2459228B1 (fr) | 2020-03-04 |
PE20120918A1 (es) | 2012-08-14 |
CA2769340A1 (fr) | 2011-02-03 |
EP2459228A1 (fr) | 2012-06-06 |
WO2011012718A1 (fr) | 2011-02-03 |
US20120184489A1 (en) | 2012-07-19 |
CN102548583A (zh) | 2012-07-04 |
BR112012002168A2 (pt) | 2016-05-31 |
ZA201200223B (en) | 2012-09-26 |
CL2012000248A1 (es) | 2012-08-31 |
SG178193A1 (en) | 2012-03-29 |
AU2010277559B2 (en) | 2016-08-11 |
US9457066B2 (en) | 2016-10-04 |
TN2012000011A1 (en) | 2013-09-19 |
CA2769340C (fr) | 2018-09-11 |
NI201200012A (es) | 2012-08-08 |
RU2012107542A (ru) | 2013-09-10 |
KR20120089843A (ko) | 2012-08-14 |
CN102548583B (zh) | 2015-04-22 |
NZ598021A (en) | 2014-05-30 |
JP2013500951A (ja) | 2013-01-10 |
CO6491083A2 (es) | 2012-07-31 |
US9138462B2 (en) | 2015-09-22 |
IL217778A (en) | 2015-10-29 |
AU2010277559A1 (en) | 2012-02-23 |
JP5738291B2 (ja) | 2015-06-24 |
CR20120018A (es) | 2012-04-18 |
MX2012001399A (es) | 2012-03-21 |
IL217778A0 (en) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
MA34517B1 (fr) | Promédicaments comprenant un conjugué exendine-lieur | |
MA33608B1 (fr) | Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations | |
MA35576B1 (fr) | Nouveaux composés | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
MA38837B1 (fr) | Inhibiteurs de l'autotaxine contenant un noyau à cycle benzyle-amide cyclique hétéroaromatique | |
MA34083B1 (fr) | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques | |
MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
BRPI0414581A (pt) | derivados de benzimidazol: preparação e aplicações farmacêuticas | |
MA31845B1 (fr) | Pipéridino-dihydrothiénopyrimidines substituées | |
MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
MA34721B1 (fr) | Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation | |
EA200801184A1 (ru) | Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2 | |
MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
MA34474B1 (fr) | Agonistes de gpr40 | |
MA35513B1 (fr) | Compositions pharmaceutiques comprenant 40 - o - ( 2 - hydroxy) éthyl - rapamycine | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
ATE487720T1 (de) | 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer | |
TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
MA35638B1 (fr) | 2-thiopyrimidinones | |
MA33299B1 (fr) | Nouvelle formulation de naproxène | |
MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 |